Lower dose of newer clot-buster may be appropriate for some stroke patients
LOS ANGELES, Feb. 20, 2020 — New research confirms that the lower 0.25mg/kg dose of the clot-busting agent tenecteplase is appropriate for eligible stroke patients and can reduce the need for mechanical clot removal, according to late breaking science presented today at the American Stroke Association’s International Stroke Conference 2020. The conference, Feb. 19-21 in…